TNFRSF11A and non-small cell lung carcinoma: This genetic modeling in the mouse supports findings in human clinical trials in which RANK inhibition with the monoclonal antibody Denosumab resulted in prolonged survival, especially in patients with non-small cell lung cancer (NSCLC) adenocarcinomas and squamous tumors.